Publications by authors named "Y Kamada"

Abnormal chromosome segregation (ACS) in preimplantation embryos causes miscarriages. For a normal pregnancy, it is necessary to reduce ACS occurrences in embryos. However, the causes of such abnormalities are unclear because no method to extract the segregated chromosomes from the blastomeres for detailed analysis.

View Article and Find Full Text PDF

Objectives: The diagnosis of early-onset Alzheimer's disease (EOAD) can cause emotional stress not only to the patients themselves but also to their spouses. This study aimed to evaluate the risk of psychiatric disorders in spouses of EOAD patients, using psychotropic drug initiation as a surrogate indicator.

Methods: A cohort study was conducted using a Japanese claims database, with spouses of EOAD patients (exposed spouses) matched with spouses of non-EOAD individuals (reference spouses) up to a 1:10 ratio.

View Article and Find Full Text PDF

Permanent preservation of genetic resources may be indispensable for the future of humanity. This requires liquid nitrogen, as is the case for preserving animal sperm. However, this technique is expensive and poses a risk of irrecoverable sample loss on non-replenishment of liquid nitrogen in case of natural disasters.

View Article and Find Full Text PDF
Article Synopsis
  • The study assessed the effectiveness of serum type 4 collagen 7S (COL4-7S) compared to the Enhanced Liver Fibrosis (ELF) score in detecting liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
  • Among 1,368 patients, 794 were analyzed, revealing that both COL4-7S and ELF scores rise with increasing fibrosis, but COL4-7S showed significantly better performance for identifying advanced fibrosis (≥2) especially in diabetic patients.
  • Overall, COL4-7S proved to be at least as effective as the ELF score in diagnosing advanced liver disease in MASLD patients.
View Article and Find Full Text PDF

Mac-2 binding protein glycosylation isomer (M2BPGi) is a liver fibrosis biomarker that originated in Japan and has been covered by health insurance for 10 years. M2BPGi is useful not only for liver fibrosis stage prediction but also for assessment of the degree of liver inflammation and prediction of hepatocellular carcinoma development. The usefulness of M2BPGi for assessing disease progression in patients with various chronic liver diseases has been demonstrated over the past decade in a large number of patients.

View Article and Find Full Text PDF